Please ensure Javascript is enabled for purposes of website accessibility

U.S. Will Export up to 60 Million Doses of AstraZeneca Coronavirus Vaccine

By Eric Volkman - Apr 26, 2021 at 6:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

10 million of that total could ship out within weeks.

Clearly addressing concerns and criticism about global coronavirus vaccine inequality, the White House said Monday it will begin sharing doses with foreign countries. The administration's Jen Psaki said that the government would provide up to 60 million doses of AstraZeneca's (AZN -0.18%) AZD1222 for such nations.

While the AstraZeneca jab is readily available in this country, it has not yet been authorized or approved for use by the FDA, so it cannot be administered here. 

Child getting a shot from a medical professional.

Image source: Getty Images.

AZD1222, which was developed in collaboration with researchers at the University of Oxford, has received such nods in various countries outside our borders. These include Oxford's home of the U.K. and India, a relatively poor country that is currently experiencing a frightening surge of coronavirus infections and COVID-19 fatalities.

Although the country would still be in desperate need of vaccines even if it were to receive all of the U.S. supply, any amount will help alleviate the crisis.

In her remarks, Psaki said the government could clear 10 million doses of the AstraZeneca jab for export in the next few weeks. The remaining 50 million are currently in production; they could be shipped out starting next month.

The Feds have not yet determined where their supply of AZD1222 will be directed, nor how they will allot them country by country. Psaki said only that "We will consider a range of options from our partner countries and, of course, much of that will be through direct relationships."

AstraZeneca shareholders didn't react strongly to the news. The company's stock essentially traded in concert with the S&P 500 index on Monday, inching up to close the day 0.2% higher. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.95 (-0.18%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.